glp-1 receptor agonist type 1 diabetes randomized trial Efficacy and safety of LY3298176, a novel dual GIP and agonist, in patients with 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 Is biased agonism helpful in

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it targets two receptors rather than one

GLP-1 receptors are also found in the hippocampus, a key structure for learning and memory

In contrast to generic medicines which are exact copies of chemically synthesised branded drugs, biosimilars closely resemble the structure and function of their reference product and are produced in modified living organisms like yeast and bacteria

No oral semaglutide

21 Our findings from this study demonstrate that amycretin is a potent agonist of GLP-1R and AMYR, and in vivo PK data showed a t 1/2 of 29 h in NHPs after i.v

Synaptic Protection and Neurogenesis They enhance synaptic plasticity and hippocampal neurogenesis, potentially mitigating cognitive decline in vascular dementia [13]